Method of producing derivatives of alkanes or alkenes

专利摘要:
The invention provides novel compounds of the formula or wherein R1 is hydrogen, hydroxy, alkoxy of 1 to 4 carbon atoms, benzyloxy, allyloxy, 2,3-epoxypropoxy, 2,3-dihydroxypropoxy, methoxymethoxy, ethoxymethoxy, or wherein one of R5 and R6 is hydrogen or R5 and R6 are alkyl groups of 1-4 carbon atoms which may be the same or different, or the -NR5R6 group stands for a nitrogen containing 5 to 7 membered heterocyclic radial and m is 1 or 2; R2 is an alkyl of 1 to 4 carbon atoms wherein R7 has the same meanings as R1, except that R7 and R, cannot simultaneously be the same; R3 is an alkyl of 2 to 4 carbon atoms, cyclopentyl or hydroxy-cyclopentyl; R4 is hydrogen or hydroxy; and n is 0 to 3, provided that when R4 is hydrogen, then R2 and R3 are not simultaneously lower alkyl containing up to 4 carbon atoms, and their non-toxic pharmaceutically acceptable acid addition salts and esters and mixtures thereof. Processes for the preparation of these compounds are described, as are novel pharmaceutical compositions of the compounds or their salts. The compounds and their non-toxic salts exhibit valuable pharmacological properties as estrogenic, anti-estrogenic, progestanic and anti-tumour activity. Certain compounds of the group are useful as chemical intermediates for the preparation of pharmaceutically active compounds of the invention.
公开号:SU1329615A3
申请号:SU823503159
申请日:1982-10-18
公开日:1987-08-07
发明作者:Седервалл Марья-Лиза；Ойва Антеро Куркела Кауко；Иоханнес Карьялайнен Арто；Юхани Тойвола Реййо；Вейкко Матти Кангас Лаури；Луис Бланко Гуйлермо
申请人:Фармос Ихтюмя Ой (Фирма)；
IPC主号:

专利说明:

M fL-i ieiine oib iiirrn new lipo-. ; 1kkaioi um plkenon common i. mmul:
RI CY CH;; - I i-Rii I. P
1; i
.: i) i MecTiio ozna -1 and ill X g 1LUT communication
,, - Oh SI-, uroxy-, dimethylamottof and the group;
: „- f (gi1l-, 1-hydroxyfennl, p - meT 1K1 if (Inl;
p - CP podentyl;
P hodod,
which can be used. as biologically active compounds in medicine.
The aim of the invention is to develop a process for the preparation of new alkanoch derivatives or alkenes, which, compared with the known compounds, have a higher activity.
The compounds obtained according to the inventive method show estrogen, anti-estrogen, progesterone and antitumor activity.
The affinity for estrogen receptors is determined by the ability of molecules to compete with H-estradiol-1 7 -α in the cytosolic preparation of a rat uterus. After incubation, the ligand cBH jaHiftie and unrelated to the receptor are separated in a known manner of dextranacase coal.
The estrogenic - antiestrogenic (progesterone - antiprogesterone) effect in vivo is determined as follows.
The estrogenic properties of the molecules are determined by injecting the molecules suspended in sesame oil, subcutaneously, which have not reached puberty, at the age of 21 days successively for three days. On the fourth day, the mice are killed and the uterus is weighed. EstradioL (control reagent) increases the weight of the uterus. Weight correlates with the estrogenic effect of molecules.
The anti-estrogenic effect of molecules is determined in the same way on mice that have not reached puberty. In this case, the ability of the molecules to inhibit estrogen-induced uterine weight gain is also analyzed.
Q
five
0 b
about

at
five
0
five
(Lnti) iroges rtpOHHbiii study in a similar way. Medroxyprogesterone acetate is used as a control reagent.
The antitumor effect is studied in vitro as follows.
The growth of the MSH-7 cell line (breast adenocarcinoma) of a human being that is estrogen-dependent is evaluated in the presence or absence of estradiol, medronrogesterone acetate or the molecules under study. The combinations of the molecule under study with estradiol and the molecule under study with medrogesterone acetate are also studied.
The number of living cells after 4, 24 and 48 h of incubation is assessed using bioluminescent analysis (determination of intracellular ATP).
The antitumor effect is studied in vivo on rat mammary adenocarcinomas caused by DMBA and transplantable breast adenocarcinomas by the following methods.
Breast adenrkarcinomas induce shvu in female rats aged 35-40 days. Treatment with the tested molecules begins after the appearance of a groping tumor. Tumor size and number of tumors are estimated twice per month. The size of the tumors in the control group, where animals are treated with solvent, is compared with the test groups.
Transplanted rat mammary adenocarcinoma develops after grafting pieces of carcinomas induced by suture, subcutaneously, to healthy female rats that have reached puberty. A tumor that shows malignant growth is selected for subsequent transplantations.
The proposed substances exhibit good affinity for estrogen receptors, as measured by the dextran-coal method.
In tab. I shows examples of the affinity for the estrogen receptor of certain compounds in the proposed method, where affinity is the concentration of the substance at which 50% competitiveness (inhibition) with H-estradiol occurs;
+++ - 10 (inhibition) - 10 M
(weak affinity); ++ - 10 (inhibition) - (weak affinity);
- 1 0- (ngbibrodne) - M
(weak affinity); - (no pronounced inhibited ani),
Table 1
(Z) -2-Cyclopentyl-1 - p- {M-methyl-2-amino-ethoxy) phenyl -1-phenyl-butsn, hydrochloride
2-C1P lopentyl-1 (N, G1-dimethyl-2-amino ethoxy) phenyl -1-Sp-methoxyphenyl) -1 -buthene, a mixture of E- and Z-isomers
2-Ethyl-3- (p-hydroxyphenyl) -1-pentanol
The substances according to the proposed method can be characterized as substances that can be estrogenic or anti-estrogenic, or possess one or other properties, in addition, they can have an inhibitory or synergistic effect with medroxyprogesterone.
The estrogenic effect of the compounds according to the proposed method, measured by their ability to increase the weight of the uterus of a mouse that has not reached puberty, is usually much lower than that of estradiol, which serves as a positive control. In tab. 2 shows examples of the estrogenic receptor ability of some compounds in the proposed method as compared with the known ones with similar relative structure.
Table

+++
3-Ethyl-4-phenyl-3-hexane
ten
15
20
25
-
thirty
2-Cyclopentyl-1- (p-methoxyphenyl) -I-phenyl-1-butene
2-Cyclopentyl1- (p- (I, P-dimethyl-2-amyluthoxy) phenyl
1 - (p-methoxy)
Nile) -1-butene
(Z + E)
2-Cyclopentyl- - (p- (H, G1-dimethyl-2-amino-ethoxy) phenyl-1- (p-hydroxyphenyl) -1-butene (Z + E)
2-Cyclopentyl- 1- (p-hydroxy-phenyl) -1-phenyl-butane (erythro + threo)
 one
Continued: and l.
:: iZT i :::
+ + lie active
2, 5-Dima til-3-fep,
hexane
Not active
+++
five
0
five
0
five
Most of the compounds have an anti-estrogenic effect, measured by their ability to inhibit the increase in the weight of the uterus of a mouse that has not reached puberty, caused by estradiol.
The progesterone and anti-progesterogenic effects of the compounds are measured by this method. A decrease in the uterine forest of the mouse caused by the compound 2 2-cyclopentyl- - (N, H-dimethyl-2-aminoethoxy) -phenyl -1- (g-methoxyphenyl) -1-butene (a mixture of E and Z-isomers ), can only be attributed to its progesterone effect. With the introduction of this substance alone, it causes a 20% reduction with a dose of 0.5 mg / kg, and together with medroxyprogesterone acetate - a 67% decrease compared with 40% caused by medroxyprogesterone alone. Acute toxicity orally in mice ranged from 1,200 to 2,000 mg / kg for the tested compounds.
The antitumor effects of the compounds are tested in vitro on the lactose adenocarcinoma cell line 51329615
Human MSH-7 episodes on adenocarcinox of the mammary gland of rats induced by MBA and transplanted with adenomastoma of the mammary gland.
Tab. 3 presents data on the rotivoviral effect of in vitro tests against the adrenocarcinoma cell line cheloeka MS-7,
the concentration of the compound at which you can see 50% inhibition of cell growth de effect 1C, o .-) 0
t5
+++
++
+
1-Ь
5 X 5 X Yu - Yu - M;
 five
go - m
M: M;
ten
-five
And, for me, I am the ol barrels and the ba bots and hers from the ET table 3
+++
++
++ ++
+++
Known
3-Ethyl-4-phenyl-3-hexane-2,5-dimethyl-3-phenyl-hexane
The antitumor effect in vivo against ShVA-induced breast carcinoma is investigated by this method.
Effect of the compound on rat mammary adenocarcinoma transplanted compared with the control, which is 100%:
obes, mg / kg, about example 2
1.0
5.0
10.0
20.0
AO, O
Relative size compared to control
87 55
87
50
50
0
five
0
five
0
five
0
Example 1. 2-Cyclopentyl-1- (p-hydroxyphenyl) -1-phenyl-I-butene. A, 7 g (0.015 mol) of 2-cyclopentyl-1- (p-hydroxyphenyl) -1-phenyl-butanol is dissolved in 100 ml of methylene chloride, and 4 ml of trifluoroacetic acid are added dropwise. The mixture is stirred at room temperature for 1 hour, then left to dry. The product is dissolved in toluene and washed with water. Dilute sodium hydroxide is added and the resulting sodium salt of the product (3.5 g) is filtered off. The sodium salt is suspended in toluene and dilute hydrochloric acid is added to release toluene from its salt. The toluene solution is washed with water, dried and evaporated. Then it is very carefully separated by fractional crystallization from petroleum ether to obtain first the E-isomer, and then the Z-isomer. M.p. Z-isomer 111.5-112.6, and Eisomer - 109-109 ,.
five
E-isomer:
 H-NMR: 0.87 (t, 3N); 1.2-1.9 (t, BH); 2.09 (q, 2H); 2.5-3.0 (t, IH); 4.7 (s, 2H); 6.70 (d, 2H); 7.05 (d, 2H); 7.0-7.5 (t, 5H).
 C-NMR: 15.23 q; 21.52 t; 25.64 t; 31.64 t; 44.14 d; 114.91 d; 125.78 d; 127.92 d; 128.99 d; 130.38 d; 136.59 s; 138.04 s; 142.86 s; 144.19 s; 153.57 s.
T.PL. propionate 65.6-67.5 ° C, T.PL. benzoate 134-I36 ° C.
Z-isomer:
H-NMR: 0.85 (t, 3H); 1.2-1.9 (rn, 8H); 2.07 (q, 2H) -; 2.5-3.0 (m, IH); 4.7 (s, IH); 6.70 (d, 2H); 7.02 (d, 2H); 7.0-7.5 (m, 5H).
 C-NMR: 15.26 q; 21.52 t; 25.64 t; 31.67 t; 44.05 d; 114.89 d; 125.81 d; 127.96 d; 129.11 d; 130.26 d; 136.62 s; 138.07 s; 142.73 s; 144.13 s; 153.60 s.
Example. 2. 2-Cyclopentyl-1- (n-methoxyphenyl) -1-phenyl-1-butene. 2-Cyclopentyl-1- (p-methoxyphenyl) -1-phenyl-1-butene is obtained from 6.5 g (0.02 mol) of 2-cyclopentyl- (p-methoxyphenyl) -phenylbutanol by the method of Example 1. At the end After dehydration, the mixture is evaporated to dryness, the precipitate is dissolved in toluene and washed with a dilute solution of sodium bicarbonate and water. After evaporation of the solvent, 5.75 g (94%) of product is obtained.
0

in the form of a mixture of E- and /.- isomerism in a ratio of 6: 4, but the isomer can be obtained from 92; cleaned recrystallization from methanol. M.p. 78-85 Yield 94%.
Pure E and Z isomers are obtained from the corresponding phenolic isomers (e.g., Example 1) by methylation with dimethyl sulfate in ethanol solution, alkalizing with sodium hydroxide using tetrabutylammonium hydrogen sulphate as a catalyst. T. pl. for the Z-isomer 88-90 C, and for the E-isomer 45-47 C.
E-isomer:
.1 NMR: 0.88 (1, 3N); 1.1-1.8 (complex, 8H); 2.10 (q, 2H); 2.78 (t.


1H); 3.73 (s, 3N); 6.78 (d, 2H); 7.11 m p-hexane. M.p. L 12-120 C. He prrd- (d, 21P; 7.0-7.5 (complex, 5H).
1 C-NMR: 15.28 q; 21.61 t; 25.66 t; 31.67 t; 44.17 d; 55.10 q; I 13.46 d; 125.75 d; 127.90 d; 128.99 d; 130.17 d; 136.35 d; 138.22 s; 142.70 25 (s, 6H); 2,779 (t, 2H); 4.083 (t.
is a mixture of 1: 1 E-and-.-something. Yield 60%
 H-NMR: 0.843 and 0.853 (t, 3fl); 1.1-1.8 (m, 8H); 2.079 (q, 2H); 2.38
s; 144.22 g; 157.78 s. Z-isomer:
 n-NMR: 0.86 (t, 3N); 1, 1-1.8. (complex, 8H); 2.07 (q, 2H); 2.78 (t, 1H); 3.73 (s, 3N); 6.78 (d, 2H) 7.09 (d, 2H); 7.0-7.5 (comp. 5H).
 C-NMR: 12.26 q; 21.61 t; 25.64 t; 31.67 t; 44.08 d; 55.10 q; 11.34 d; 125.75 d; -127.96 d; 1269.11 d; 130.05 d; 136.35 s; 138.22 s; 142.58 s; 144.19 s; 157.78 s.
Example 3. 2-Cyclopentyl-1- n - (, K-dimethyl-2-aminoethoxy) -phenyl - - (h-methoxyphenyl) -1-butene (mixture of E-Z-isomers). 2-Cyclopentyl- - (H, H-dimethyl-2-aminoethoxy) -fe- (p-methoxyphenyl) -butylene (mixture of E- and Z-isomers) is obtained in Example 5. 2-cyclopentyl-2- (u-methoxyphenyl A) -1-phenylbutane is obtained by catalytic hydrogenation of 1.5 g (4.9 mmol) of 2-cyclopentyl-1- (p-methoxyphenyl) -1-phenyl-1-butylene, dissolved in 25 ml of absolute ethanol and using 75 mg 10 % Pd-C as a catalyst. Hydrogen uptake is 115 ml. The catalyst is filtered off and the solution is evaporated to dryness. Yield 1.49 g (99%). Product is
40
„, 0 fr 1 Olc is a mixture of threo and erythro isomers.
hydration 4.8 g (0.012 mol) 2-cyc-. Jg 5h (2t, 3N); lopentil-l-Ln- (N, N-dimethyl-2-amine- (t, 11H); 2 20 (sh, 1H); 3.73
ETOXI) -rtlP4Hn 1- - (h -MPTnvrurtioHMn 1--....,
ethoxy) phenyl -1- (i-methoxyphenyl) butanol in methyl trichloride using trifluoroacetic acid as a dehydrating agent as in example 1. The procedure is continued as in example 2. The yield of the mixture of E and Z-eomers is 4.15 g (88%).
 H-NMR: 0.86 (t, 3N); 1.2-1.8
(complex, 8H); 2.08 (q, 2H); 2.32
i
(s, 6H); 2.70 (t, 2H), under which (t,
1H); 3.76 (s, 3N); 4.03 (t, 2H); 6.79 (d, 4H); 7.0 and 7.06 (2d, 4H).
73
(d, IH); 6.77 (d, 2H); 7.22 (d, 2n: 7.0-7.5 (ha, 5H).
5Q Example 6. 2-Cyclopentyl-1 - (p-hydroxyphenyl) -1-phenylbutane is hydrotinated by the method of Example 5 of 1, 5 g mmol) 2-cyclopentyl-1- (p-hydroxyphenyl) -1-phenyl-1- butylene
55 Yield 1.48 g (99%).
 n-NMR: 0.681 and 0.694 (2d, 3N); -1.0-2.0 (t, 11H); 2.20 (t, 1H); 3.70 (d, 1H); 6.68 (d, 2H); 7.13 (d, 2H); 7.0-7.5 (t, 5H). Pure erythro and
t; q;
; C-NMR: 31.67 t;
5.26 4.14
2.58
 J
9 about:
 ) 55
65.96 t; 1 13.37
h, 10
3.9
0
q; 58.40
d and 1 14.07 d; 130.02 and 130, Mid; 136.71 and 136.77 p; 137.68 g .; 142.49 s; 156.96 s; 157.66 -.
Example 4. 2-Cpklopentyl-1-1 - (M, H-dimethyl-2-aminoethox) 0 -phenyl 1 (g. Is hydroxyphenyl) -1 -butene (cmpy
E and G.-isomers). 2-Cyclopentyl-1-p- (H,) -dimethyl-2-aminoethoxy) -phenyl - 1 - (p-hydroxyphenyl) -1-butanol prepared from "-cyclopentyl-fi-hydroxy-15 butyrophenone and p- ( N, -dimethyl-2-aminoethoxy) bromobenzene using the method of Example 3, is dehydrated into ethanol in the presence of hydrochloric acid. The product is recrystallized from
n-hexane. M.p. L 12-120 C. He prrd-
(s, 6H); 2,779 (t, 2H); 4.083 (t.
is a mixture of 1: 1 E-and-.-something. Yield 60%
 H-NMR: 0.843 and 0.853 (t, 3fl); 1.1-1.8 (m, 8H); 2.079 (q, 2H); 2,383
,
2H); 6.68 (d, 4H); 6.8-7.1 (t, 4H). C-NMR: 15.29 q; 21.58 q; 25.64 t; 31.67 t; 44.14 d; 45.41 q; 58.09 t; 65.15 t; 113.95 d; 115.16 and 115.22 0 d; 130.14 and 130.23 d; 135.74 s;
137.10 s; 142.5 s; 154.84 s; 156.60 s.
Example 5. 2-iiclopentyl-2- (u-methoxyphenyl) -1-phenylbutane is obtained by catalytic hydrogenation 1.5 g (4.9 mmol) of 2-cyclopentyl-1- (p-methoxyphenyl) -1-phenyl-1-butylene dissolved in 25 ml of absolute ethanol and using 75 mg of 10% Pd-C as a catalyst. Hydrogen uptake is 115 ml. The catalyst is filtered off and the solution is evaporated to dryness. Yield 1.49 g (99%). Product is
0
. Jg 5h (2t, 3N); (t, 11H); 2 20 (sh, 1H); 3.73
. . . . ,,
73
(d, IH); 6.77 (d, 2H); 7.22 (d, 2n: 7.0-7.5 (ha, 5H).
Example 6. 2-Cyclopentyl-1 - (p-hydroxyphenyl) -1-phenylbutane is hydrogenated by the method of Example 5 of 1.5 g mmol) 2-cyclopentyl-1- (p-hydroxyphenyl) -1-phenyl-1- butylene.
The output of 1.48 g (99%).
 n-NMR: 0.681 and 0.694 (2d, 3N); -1.0-2.0 (t, 11H); 2.20 (t, 1H); 3.70 (d, 1H); 6.68 (d, 2H); 7.13 (d, 2H); 7.0-7.5 (t, 5H). Pure erythro and
The threo isomers can be obtained by hydrogenating the pure Z and E isomers of the starting materials, respectively.
Thus, the obtained new biologically active substances have a broader spectrum of activity and activity than the known ones.

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining alkanes or alkenes of the general formula
 CY-CH2.-CH2-R i g
where X Y - H or X and Y together mean a bond;
Editor And, Shulla
Compiled by M. Merkulova
Tehred M. Khodanych Proof-reader V. But ha
Order 3499/58 Circulation 371Subscription
VNIIPI USSR State Committee
for inventions and discoveries 113035, Moscow, Zh-35, Raushsk nab., d, 4/5
Production and printing company, Uzhgorod, st. Project, 4
2961510
R-, - OXY-, methoxy-, d} 1methylaminoethoxy;
R is phenyl, p-hydroxyphenyl, p-met-5 hydroxyphenyl,
R} is cyclopentral; R is hydrogen,
characterized in that the compound of the general formula
g
ten
 c-cH-cH-cH -R (t
: ii)
 I
where R, R, Rj, R4 - are as defined above, are dehydrated in the presence of acids such as HC1, CFjCOOH to give a compound of formula (I), where X and Y mean a bond which, if necessary, is subjected to catalytic hydrogenation in tNol to give a compound of the formula where XY is N.

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1508955A3|1989-09-15|Method of producing alkene derivatives or their salts

---

US6037362A|2000-03-14|Tricyclic compounds and drug compositions containing the same

---

KR101717098B1|2017-03-16|Diglycidic ether derivative therapeutics and methods for their use

---

EP1709155B1|2013-10-02|Compounds and compositions for treating dysproliferative diseases, and methods of use thereof

---

SU1329615A3|1987-08-07|Method of producing derivatives of alkanes or alkenes

---

IE51882B1|1987-04-15|1,2,2-triphenyl but-1-ene derivatives as well as a method for their production and their use as a pharmaceutical preparation

---

EP0772591A1|1997-05-14|2-phenyl indoles as anti-oestrogen drugs

---

EA017038B1|2012-09-28|Progesterone receptor antagonists

---

FUJITA et al.1981|Antitumor activity of acylated oridonin

---

RU2320669C2|2008-03-27|Purposeful chemotherapy of gonad tumor

---

EA004931B1|2004-10-28|3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same

---

AU650429B2|1994-06-23|Novel aryloxy alcoyl benzenes, processes for their preparation as well as the pharmaceutical compositions containing them

---

Korach et al.1987|Estrogen receptor stereochemistry: receptor binding and hormonal responses

---

Schneider1986|2-Alkyl-substituted 1, 1-bis |-2-phenylethenes. Estrogen receptor affinity, estrogenic and antiestrogenic properties, and mammary tumor inhibiting activity

---

EP0011372B1|1983-02-09|1-acyloxyphenyl-1,2-diphenylalkene derivatives, processes for their manufacture and a pharmaceutical composition containing these derivatives

---

Browne et al.1952|Isomeric Amino Alcohols from the Reaction of Styrene Oxide with Benzylamine

---

RU2060249C1|1996-05-20|Polycyclic biocide compounds and pharmaceutical composition on their base

---

IE902242A1|1991-01-16|Novel Spirofurane Derivatives

---

Schneider et al.1986|Catechol estrogens of the 1, 1, 2-triphenyl-1-butene type. Relationship between structure, estradiol receptor affinity, estrogenic and antiestrogenic properties, and mammary tumor inhibiting activities

---

US6288249B1|2001-09-11|Vitamin D analogs and methods of preparing these compounds

---

BE1001235A4|1989-08-29|Azole DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DRUGS.

---

PL131227B1|1984-10-31|Process for preparing novel derivatives of 1,1,2-triphenyl-propene

---

US10064837B1|2018-09-04|Abietic acid derivatives as anti-tumor agents

---

FR2973376A1|2012-10-05|DERIVATIVES USEFUL IN THE TREATMENT OR PREVENTION OF BONE TUMORS

---

US20020161007A1|2002-10-31|Non-steroidal modulators of estrogen receptors

同族专利:

---

公开号 | 公开日

---

FI823465L|1983-04-27|

---

FI823465A0|1982-10-12|

---

US4556677A|1985-12-03|

---

ZA827742B|1983-08-31|

---

CA1310974C|1992-12-01|

---

NZ202269A|1985-05-31|

---

JPS5879934A|1983-05-13|

---

NO159079C|1988-11-30|

---

GB2108486B|1986-01-29|

---

HU193268B|1987-09-28|

---

FI77842B|1989-01-31|

---

AT22065T|1986-09-15|

---

EP0078158B1|1986-09-10|

---

DE3273219D1|1986-10-16|

---

GB2108486A|1983-05-18|

---

IE54586B1|1989-12-06|

---

IE822551L|1983-04-26|

---

EP0078158A3|1984-01-18|

---

NO159079B|1988-08-22|

---

IL67049A|1987-07-31|

---

DD211548A1|1984-07-18|

---

JPH0239492B2|1990-09-05|

---

AU8970282A|1983-05-12|

---

NO823537L|1983-04-27|

---

DK472082A|1983-04-27|

---

AU555477B2|1986-09-25|

---

EP0078158A2|1983-05-04|

---

FI77842C|1989-05-10|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

RU2496880C2|2008-12-12|2013-10-27|СЕЛЕКСИОН, ЭлЭлСи|Biological synthesis of difunctional alkanes from alpha-keto acids|FR1306604A|1959-03-03|1962-10-19|Ferrosan Ab|Process for preparing substituted bisphenylethylenes|

---

GB1289966A|1968-12-24|1972-09-20|

---

US3661976A|1969-05-16|1972-05-09|Parke Davis & Co|4,4'- diphenols and ethers and esters thereof|

---

BE793686A|1972-01-07|1973-07-04|Beecham Group Ltd|BIOLOGICALLY ACTIVE DI-ARYL COMPOUNDS|

---

GB2108486B|1981-10-26|1986-01-29|Farmos Group Ltd|Alkane and alkene derivatives and their preparation and use|GB2108486B|1981-10-26|1986-01-29|Farmos Group Ltd|Alkane and alkene derivatives and their preparation and use|

---

US4760053A|1984-08-02|1988-07-26|Fernand Labrie|Combination therapy for selected sex steroid dependent cancers|

---

US4775660A|1984-08-02|1988-10-04|Fernand Labrie|Treatment of breast cancer by combination therapy|

---

US4666885A|1985-02-08|1987-05-19|Fernand Labrie|Combination therapy for treatment of female breast cancer|

---

US4895715A|1988-04-14|1990-01-23|Schering Corporation|Method of treating gynecomastia|

---

DE69022722T2|1989-03-10|1996-05-02|Endorecherche Inc|COMBINATION THERAPY FOR TREATING ESTROGEN SENSITIVE DISEASES.|

---

NL1018247C2|2001-06-08|2002-12-10|Sara Lee De Nv|Device for preparing a beverage suitable for consumption such as coffee.|

---

JP2004010479A|2002-06-03|2004-01-15|Japan Science & Technology Corp|New solid pharmaceutical preparation comprising block copolymer and anthracycline anticancer agent, and method for producing the same|

---

FR3071837B1|2017-09-29|2019-11-01|Institut National De La Recherche Agronomique|CHEMICALLY STABLE LIGNIN DERIVATIVE AND PROCESS FOR PREPARING THE SAME|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

GB08132240A|GB2108486B|1981-10-26|1981-10-26|Alkane and alkene derivatives and their preparation and use|

---